NOT FOR RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL.
RESULT OF BOOKBUILD
Cambridge, UK, 5 April 2017 – Abzena plc (“Abzena” or the “Company”) is pleased to announce the result of the bookbuild announced earlier today (the “Placing”).
A total of 75,757,576 new ordinary shares of £0.002 each in the Company (the “Placing Shares”) representing approximately 55.0 per cent. of the Company’s existing issued ordinary share capital (excluding any treasury shares) have been conditionally placed at a price of 33 pence per Placing Share (the “Placing Price”) raising proceeds of approximately £25 million (before expenses), subject to completion of the Placing.
The Placing Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of their issue.
Numis Securities Limited (“Numis”) and N+1 Singer Advisory LLP (“N+1 Singer”, and together with Numis, the “Joint Bookrunners“) have acted as joint bookrunners in respect of the Placing. Numis is acting as nominated adviser to the Company.
Other than where defined, capitalised terms used in this announcement have the meanings given to them in the announcement released by the Company this morning at 7.00 a.m.
Circular to be posted today
Further to this announcement that it has conditionally raised gross proceeds of approximately £25 million through a placing of new Ordinary Shares, Abzena is pleased to announce that a circular (the “Circular“) will be posted today notifying shareholders of a general meeting which is being convened for the purpose of considering the resolutions required in connection with the Placing, at The Cambridge Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT at 10.00 a.m. on 21 April 2017.
A copy of the Circular will shortly be available online at www.abzena.com.
John Burt, Chief Executive Officer
Julian Smith, Chief Financial Officer
+44 1223 903498
Numis (Nominated Adviser and Broker)
Clare Terlouw / James Black / Paul Gillam
+44 20 7260 1000
N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong / Mark Taylor
+44 20 7496 3069
Melanie Toyne Sewell / Alex Shaw
+44 20 7457 2020
Notes to Editors
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term ‘Abzena inside’ is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ‘Abzena inside’ products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;
- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
- Cell line development for the manufacture of recombinant proteins and antibodies;
- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
This Announcement should be read in its entirety: